




INFLUENZA ACTIVITY UPDATE: 2022-2023 Influenza Season

January 26, 2023

Alicia Budd, MPH
Influenza Division, CDC



1




2

Virologic Surveillance – Virus Characteristics



Influenza Positive Tests Reported to CDC by Public Health Laboratories, National Summary, 2022-23 Season, week ending Jan 14, 2023
Reported by U.S. WHOINREVSS Collaborating Laboratories and ILINet

- A (H1)
- A (Unable to Subtype)
- A (H3)
- A (H1N1)pdm09
- A (Subtyping not Performed)
- B (Lineage Unspecified)
- H3N2v
- B (Victoria Lineage)
- B (Yamagata Lineage)
- No Data/Small Data Sample



- 99.6% influenza A
 - 77% H3
 - 23% H1
- 0.4% influenza B
 - 100% Victoria lineage



Viruses Collected in the U.S. since October 2, 2022

Virus	Genetic Characterization		Antigenic Characterization	
	Number Tested	Clade/Subclade	Number Tested	Similarity to cell-grown vaccine reference virus
A/H1	470	0.2% - 6B.1A.5a.1	74	99.9% similar
		99.8% - 6B.1A.5a.2		
A/H3	875	100% - 3C.2a1b.2a.2	103	91% similar
B/Victoria	21	9.5% - V1A.3	10	100% similar
		90.5% - V1A.3a.2		

Antiviral Susceptibility


Viruses Collected since 10/2/22

- Oseltamivir, Peramivir, Zanamivir – 1,370 tested, 0 resistant
- Baloxavir – 1,320 tested, 0 resistant

3


Outpatient Respiratory Illness

Percentage of Outpatient Visits for Respiratory Illness Reported by The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2022-2023* and Selected Previous Seasons




This system monitors visits for ILI (fever and cough or sore throat), not laboratory confirmed influenza and may capture patient visits due to other respiratory pathogens that cause similar symptoms.

Percentage of Outpatient Visits for Respiratory Illness by Age Group Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, October 2, 2022-January 14, 2023*



This system monitors visits for ILI (fever and cough or sore throat), not laboratory confirmed influenza and may capture patient visits due to other respiratory pathogens that cause similar symptoms.



ILI Activity Level


- Very High
- High
- Moderate
- Low
- Minimal
- Insufficient Data

2022-23 Influenza Season Week 2 ending Jan 14, 2023




4

Long-term Care Facilities (LTCF) and Hospitals



5


Mortality




6

Preliminary In-Season Burden Estimates, 2022-23

CDC estimates* that, from **October 1, 2022** through **January 14, 2023**, there have been:



Estimated Range of Annual Burden of Flu in the U.S. from 2010 – 2020



*Because influenza surveillance does not capture all cases of flu that occur in the U.S., CDC provides these estimated ranges to better reflect the larger burden of influenza. These estimates are calculated based on data collected through CDC's Influenza Hospitalization Surveillance Network (FluSurv-NET) and are **preliminary**.



7

Summary

- Influenza activity continues to decline in most areas of the country.
- H3N2 remains the predominant virus.
- Declining activity ≠ no activity
- Surveillance continues year-round
 - Is the virus changing?
 - Is activity increasing again?



8

Questions?
abudd@cdc.gov

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

